Sign in Subscribe

msi-h

A collection of 92 issues

COMMIT trial analysis examines chemoimmunotherapy in dMMR metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA COMMIT trial analysis examines chemoimmunotherapy in dMMR metastatic CRC A new analysis explores what the COMMIT trial can and cannot tell us about combining chemotherapy with immunotherapy in patients with deficient DNA mismatch repair metastatic colorectal cancer. (Journal of Clinical Oncology) This

Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC

Skip to content The CRC Digest ◇ RESEARCH Age-Stratified Mutation Patterns Reveal Distinct Features in Early-Onset CRC Analysis of 6,762 samples across four age groups found that early-onset colorectal cancer (diagnosed before age 50) shows different mutation patterns compared to later-onset disease, with implications for testing guidelines and therapeutic development.

CRC Research Update — September 04, 2026

Today's colorectal cancer research highlights

CRC Research Update — September 03, 2026

Today's colorectal cancer research highlights

Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC

Skip to content The CRC Digest ▸ TREATMENT Patients With Poor Performance Status Still Benefit From Immunotherapy in MSI-H CRC An international retrospective study of dMMR/MSI-H metastatic colorectal cancer patients found that immune checkpoint blockers produced durable responses even in patients with poor ECOG performance status, a group often excluded

CRC Research Update — September 02, 2026

Today's colorectal cancer research highlights

Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients

Skip to content The CRC Digest ◇ RESEARCH Russian registry study reports MSI/dMMR prevalence in 2,101 consecutive colorectal cancer patients A prospective multicenter registry enrolled consecutive, unselected patients with primary colorectal adenocarcinoma at six Moscow centers between 2022 and 2025 to establish population-level data on mismatch repair deficiency prevalence

Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC

Skip to content The CRC Digest ◇ RESEARCH Single-cell study identifies ETV4-MC1R pathway driving immunotherapy resistance in MSI-H CRC Researchers used single-cell RNA sequencing to compare PD-1-resistant and PD-1-sensitive MSI-H metastatic colorectal tumors, identifying a gene regulatory network involving ETV4 and MC1R that may explain why some MSI-H cancers don'

PET/CT metabolic parameters predict microsatellite instability status in colorectal cancer

Skip to content The CRC Digest PET/CT metabolic parameters predict microsatellite instability status in colorectal cancer Researchers developed a non-invasive nomogram model using preoperative 18F-FDG PET/CT metabolic parameters to predict MSI status in 156 CRC patients, potentially guiding personalized treatment decisions. (Rev Esp Med Nucl Imagen Mol) This

CRC Research Update — August 31, 2026

Today's colorectal cancer research highlights